2026年11月14日,国家医保局在苏州发布2026年国家医保药品目录及商业健康保险创新药品目录1。新版国家医保药品目录新增107种药品,其中包含51个一类新药,该数量创下历史新高1。调整完成后,2026年版国家医保药品目录收录的药品总数达到3331个,包括西药1935个和中成药1396个1。这些新纳入目录的药品将于2027年1月1日正式落地执行1。
与此同时,商业健康保险创新药品目录也进行了同步调整,新增12种药品1。入选的新增品种涵盖了全球首个实体瘤CAR-T疗法以及中国首个血友病基因治疗药物1。经过此次调整,2026年商业健康保险创新药品目录共收录28种药品1。
China’s National Healthcare Security Administration announced the 2026 version of the National Medical Insurance Drug List and the Commercial Health Insurance Innovative Drug Catalog in Suzhou on November 14, 2026 1. The updated national medical insurance list incorporates 107 new drugs, including 51 Class-1 new drugs, which marks a historic high for such additions 1. Following this adjustment, the total number of medications in the 2026 National Medical Insurance Drug List has reached 3,331, comprising 1,935 Western medicines and 1,396 traditional Chinese patent medicines 1.
The revised catalog is scheduled to take effect on January 1, 2027 1. In parallel, the Commercial Health Insurance Innovative Drug Catalog underwent adjustments to add 12 new entries, bringing its total count to 28 1. Notable among these new additions are the world’s first CAR-T therapy for solid tumors and China’s first gene therapy drug for hemophilia 1.
评论
还没有评论,欢迎留下第一条。